Genentech changes ranibizumab programs

Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.

South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.

The changes include:

For more information, physicians and patients may contact 866/724-9394 or http://www.lucentisaccesssolutions.com/.